Ryvu Therapeutics Sa
Clinical trials sponsored by Ryvu Therapeutics Sa, explained in plain language.
-
New hope for Tough-to-Treat lymphoma: Two-Drug combo enters Mid-Stage trial
Disease control Recruiting nowThis Phase 2 trial is testing a new drug called MEN1703, both alone and combined with another drug called glofitamab, in 178 adults with aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The study aims to see if the drugs…
Phase: PHASE2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New hope for myelofibrosis patients: experimental drug RVU120 enters Mid-Stage trial
Disease control Recruiting nowThis Phase 2 trial tests a new drug called RVU120, alone or with the standard drug ruxolitinib, in 230 adults with intermediate or high-risk myelofibrosis. The main goal is to see if the drug can shrink the spleen and improve symptoms. Participants must have not responded well to…
Phase: PHASE2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC